Skip to main content

Advertisement

SpringerLink
Log in

Desmopressin therapy in children and adults: pharmacological considerations and clinical implications

  • Review
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Abstract

Purpose

This review aims to provide prescribing clinicians a deeper appreciation of desmopressin’s clinical indications and formulation types, to better balance efficacy and safety through proper formulation selection.

Background

Since its discovery 50 years ago, desmopressin’s antidiuretic properties have been used for central diabetes insipidus, primary monosymptomatic nocturnal enuresis and adult nocturnal polyuria, while its coagulant effects are useful for mild hemophilia A and von Willebrand Disease. During this time, newer formulations of desmopressin have also been introduced to the market raising questions on interchangeability, dose conversion and safety. The wide array of clinical indications and variable pharmacokinetic properties of different desmopressin preparations raises the possibility of medication error, especially the risk of hyponatraemia.

Methodology

A narrative review to explore clinically relevant aspects of desmopressin therapy, synthesising information obtained from searches of published literature.

Results

We identified that the risk factors for developing hyponatremia include extremes of age, existing comorbidity, drug interaction, intranasal formulations and intercurrent illness. We describe the dose equivalence between all formulations to facilitate conversion. We highlight that in view of inter-subject variability, close monitoring is recommended when switching preparations. We found that paediatric data remains limited, leading to recent proposals for age- and weight-based dosing regimens.

Conclusion

The risk of hyponatremia, albeit small, can be reduced by adhering to the indication-specific doses and taking steps to govern the safe prescription of the drug. Further paediatric clinical trials are awaited to expand the evidence base of childhood desmopressin therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

Abbreviations

ADH:

Antidiuretic hormone

AUC:

Area under curve

AVP:

Arginine vasopressin

AVPR1:

Arginine vasopressin receptor 1

AVPR2:

Arginine vasopressin receptor 2

CDI:

Central diabetes insipidus

DI:

Diabetes insipidus

IM:

Intramuscular

IV:

Intravenous

MELT:

Oral lyophilisate table

OST:

Oral solid tablet

PD:

Pharmacodynamics

PK:

Pharmacokinetics

PMNE:

Primary monosymptomatic nocturnal enuresis

SC:

Subcutaneous

vWD:

Von Willebrand disease

vWF:

Von Willebrand factor

References

  1. Acher R, Chauvet J, Chauvet M-T, Crepy D (1965) Caracterisation des hormones neurohypophysaires d'un poisson osseux d'eau douce, la carpe (Cyprinus carpio). Comparaison avec les hormones des poissons osseux marins. Comp Biochem Physiol 14(2):245–54. https://doi.org/10.1016/0010-406X(65)90201-X

  2. Zaoral M, Kole J, Sorm F (1967) Synthesis of 1-deamino-8-D-amino-butyrine vasopressin, 1-deamino-8-D-lysine vasopressin and 1-deamino-8-D-arginine vasopressin. Collection of Czechoslovak Chemistry Communications 32:1250–1257

    Article  CAS  Google Scholar 

  3. Zaoral M (2008) DDAVP (Desmopressin) and solid phase peptide synthesis. Pept Sci 90(3):213. https://doi.org/10.1002/bip.20936

    Article  CAS  Google Scholar 

  4. Dimson SB (1977) Desmopressin as a treatment for enuresis. Lancet (London, England) 1(8024):1260. https://doi.org/10.1016/S0140-6736(77)92467-9

    Article  CAS  Google Scholar 

  5. Vande Walle J, Stockner M, Raes A, Norgaard JP (2007) Desmopressin 30 years in clinical use: a safety review. Curr Drug Saf 2(3):232–238. https://doi.org/10.2174/157488607781668891

    Article  CAS  PubMed  Google Scholar 

  6. Safety concerns prompt update to US labelling for desmopressin (2007) Inpharma Weekly 1617(1):17. https://doi.org/10.2165/00128413-200716170-00051

  7. MHRA (2007) Desmopressin nasal spray: removal of nocturnal enuresis indication. Drug Safety Update 1(2):7. https://www.gov.uk/drug-safety-update/desmopressin-nasal-spray-removal-of-nocturnal-enuresis-indication. Accessed 10 Oct 2021

  8. Truax BT (2016) Patient safety tip of the week: desmopressin back in the spotlight. https://www.patientsafetysolutions.com/docs/October_25_2016_Desmopressin_Back_in_the_Spotlight.pdf. Accessed 10 Oct 2021

  9. Sharman A, Low J (2008) Vasopressin and its role in critical care. Continuing Education in Anaesthesia Critical Care & Pain 8(4):134–137. https://doi.org/10.1093/bjaceaccp/mkn021

    Article  Google Scholar 

  10. Choong K (2016) Vasopressin in pediatric critical care. Journal of Pediatric Intensive Care 5(4):182–188. https://doi.org/10.1055/s-0036-1583282

    Article  PubMed  PubMed Central  Google Scholar 

  11. Phelps SJ, Hagemann TM, Lee KR, Thompson AJ (2018) Vasopressin. Pediatric injectable drugs (The Teddy Bear Book). 11th edition: Am Soc Health Syst Pharm 860–3

  12. Kim RJ, Malattia C, Allen M, Moshang JT, Maghnie M (2004) Vasopressin and desmopressin in central diabetes insipidus: adverse effects and clinical considerations. Pediatr Endocrinol Rev 2:115–123

    PubMed  Google Scholar 

  13. Karthikeyan A, Abid N, Sundaram PC, Shaw NJ, Barrett TG, Högler W et al (2013) Clinical characteristics and management of cranial diabetes insipidus in infants. J Pediatr Endocrinol Metab 26(11–12):1041–1046. https://doi.org/10.1515/jpem-2013-0026

    Article  CAS  PubMed  Google Scholar 

  14. Lim WY, Riba-Wolman R (2019) Intravenous formulation of desmopressin delivered via oral and g tube routes for the treatment of central diabetes insipidus: first experience in infants. Clin Endocrinol 92(2):179–181. https://doi.org/10.1111/cen.14125

    Article  Google Scholar 

  15. Korkmaz HA, Demir K, Kılıç FK, Terek D, Arslanoğlu S, Dizdarer C et al (2014) Management of central diabetes insipidus with oral desmopressin lyophilisate in infants. J Pediatr Endocrinol Metab 27(9–10):923–927. https://doi.org/10.1515/jpem-2013-0368

    Article  CAS  PubMed  Google Scholar 

  16. Smego AR, Backeljauw P, Gutmark-Little I (2016) Buccally administered intranasal desmopressin acetate for the treatment of neurogenic diabetes insipidus in infancy. J Clin Endocrinol Metab 101(5):2084–2088. https://doi.org/10.1210/jc.2016-1157

    Article  CAS  PubMed  Google Scholar 

  17. Mavinkurve M, McGrath N, Johnston N, Moloney S, Murphy NP, Hawkes CP (2017) Oral administration of diluted nasal desmopressin in managing neonatal central diabetes insipidus. J Pediatr Endocrinol Metab 30(6):623–628. https://doi.org/10.1515/jpem-2017-0051

    Article  PubMed  Google Scholar 

  18. Durr JA, Lindheimer MD (1996) Diagnosis and management of diabetes insipidus during pregnancy. Endocr Pract 2(5):353–361. https://doi.org/10.4158/EP.2.5.353

    Article  CAS  PubMed  Google Scholar 

  19. Ananthakrishnan S (2016) Diabetes insipidus during pregnancy. Best Pract Res Clin Endocrinol Metab 30(2):305–315. https://doi.org/10.1016/j.beem.2016.02.005

    Article  CAS  PubMed  Google Scholar 

  20. Lindheimer MD, Barron WM (1994) Water metabolism and vasopressin secretion during pregnancy. Baillieres Clin Obstet Gynaecol 8(2):311–331. https://doi.org/10.1016/S0950-3552(05)80323-2

    Article  CAS  PubMed  Google Scholar 

  21. Marques P, Gunawardana K, Grossman A (2015) Transient diabetes insipidus in pregnancy. Endocrinol Diabetes Metab Case Rep 2015(1). https://doi.org/10.1530/EDM-15-0078

  22. O’Flynn N (2011) Nocturnal enuresis in children and young people: NICE clinical guideline. Br J Gen Pract 61(586):360–362. https://doi.org/10.3399/bjgp11X572562

    Article  PubMed  PubMed Central  Google Scholar 

  23. Neveus T, Eggert P, Evans J, Macedo A, Rittig S, Tekgül S et al (2010) Evaluation of and treatment for monosymptomatic enuresis: a standardization document from the International Children’s Continence Society. J Urol 183(2):441–447. https://doi.org/10.1016/j.juro.2009.10.043

    Article  PubMed  Google Scholar 

  24. Hjälmås K, Hanson E, Hellström A, Kruse S, Sillen U (1998) Long-term treatment with desmopressin in children with primary monosymptomatic nocturnal enuresis: an open multicentre study. Swedish Enuresis Trial (SWEET) Group. Br J Urol 82(5):704–9. https://doi.org/10.1046/j.1464-410x.1998.00826.x

  25. Fritz G, Rockney R (2004) Practice parameter for the assessment and treatment of children and adolescents with enuresis. J Am Acad Child Adolesc Psychiatry 43(12):1540–1550. https://doi.org/10.1097/01.chi.0000142196.41215.cc

    Article  PubMed  Google Scholar 

  26. Peng CCH, Yang SSD, Austin PF, Chang SJ (2018) Systematic review and meta-analysis of alarm versus desmopressin therapy for pediatric monosymptomatic enuresis. Sci Rep 8(1):16755. https://doi.org/10.1038/s41598-018-34935-1

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Robson W, Leung A, Norgaard JP (2007) The comparative safety of oral versus intranasal desmopressin for the treatment of children with nocturnal enuresis. J Urol 178(1):24–30. https://doi.org/10.1016/j.juro.2007.03.015

    Article  CAS  PubMed  Google Scholar 

  28. Hashim H, Blanker MH, Drake MJ, Djurhuus JC, Meijlink J, Morris V et al (2019) International Continence Society (ICS) report on the terminology for nocturia and nocturnal lower urinary tract function. Neurourol Urodyn 38(2):499–508. https://doi.org/10.1002/nau.23917

    Article  PubMed  Google Scholar 

  29. Burgio KL, Johnson TM II, Goode PS, Markland AD, Richter HE, Roth DL et al (2010) Prevalence and correlates of nocturia in community-dwelling older adults. J Am Geriatr Soc 58(5):861–866. https://doi.org/10.1111/j.1532-5415.2010.02822.x

    Article  PubMed  PubMed Central  Google Scholar 

  30. Kupelian V, Fitzgerald MP, Kaplan SA, Norgaard JP, Chiu GR, Rosen RC (2011) Association of nocturia and mortality: results from the Third National Health and Nutrition Examination Survey. J Urol 185(2):571–577. https://doi.org/10.1016/j.juro.2010.09.108

    Article  PubMed  Google Scholar 

  31. Ancoli-Israel S, Bliwise DL, Nørgaard JP (2011) The effect of nocturia on sleep. Sleep Med Rev 15(2):91–97. https://doi.org/10.1016/j.smrv.2010.03.002

    Article  PubMed  Google Scholar 

  32. Leslie SW, Sajjad H, Singh S (2020) Nocturia. StatPearls [Internet]. https://www.ncbi.nlm.nih.gov/books/NBK518987/. Accessed 10 Oct 2021

  33. Kupelian V, Wei JT, O’Leary MP, Norgaard JP, Rosen RC, McKinlay JB (2012) Nocturia and quality of life: results from the Boston area community health survey. Eur Urol 61(1):78–84. https://doi.org/10.1016/j.eururo.2011.05.065

    Article  PubMed  Google Scholar 

  34. Weiss JP, van Kerrebroeck PE, Klein BM, Nørgaard JP (2011) Excessive nocturnal urine production is a major contributing factor to the etiology of nocturia. J Urol 186(4):1358–1363. https://doi.org/10.1016/j.juro.2011.05.083

    Article  PubMed  Google Scholar 

  35. Thüroff JW, Abrams P, Andersson K-E, Artibani W, Chapple CR, Drake MJ et al (2011) EAU guidelines on urinary incontinence. Actas Urológicas Españolas (English Edition) 35(7):373–388. https://doi.org/10.1016/j.acuroe.2011.03.002

    Article  Google Scholar 

  36. Weiss JP, Blaivas JG, Bliwise DL, Dmochowski RR, DuBeau CE, Lowe FC et al (2011) The evaluation and treatment of nocturia: a consensus statement. BJU Int 108(1):6–21. https://doi.org/10.1111/j.1464-410X.2011.10175.x

    Article  PubMed  Google Scholar 

  37. Abrams P, Andersson K-E, Birder L, Brubaker L, Cardozo L, Chapple C et al (2010) Fourth International Consultation on Incontinence Recommendations of the International Scientific Committee: Evaluation and treatment of urinary incontinence, pelvic organ prolapse, and fecal incontinence. Neurourology and Urodynamics: Official Journal of the International Continence Society 29(1):213–240. https://doi.org/10.1002/nau.20870

    Article  CAS  Google Scholar 

  38. Weiss JP, Herschorn S, Albei CD, van der Meulen EA (2013) Efficacy and safety of low dose desmopressin orally disintegrating tablet in men with nocturia: results of a multicenter, randomized, double-blind, placebo controlled, parallel group study. J Urol 190(3):965–972. https://doi.org/10.1016/j.juro.2012.12.112

    Article  CAS  PubMed  Google Scholar 

  39. Sand PK, Dmochowski RR, Reddy J, van der Meulen EA (2013) Efficacy and safety of low dose desmopressin orally disintegrating tablet in women with nocturia: results of a multicenter, randomized, double-blind, placebo controlled, parallel group study. J Urol 190(3):958–964. https://doi.org/10.1016/j.juro.2013.02.037

    Article  CAS  PubMed  Google Scholar 

  40. Juul KV, Klein BM, Sandström R, Erichsen L, Nørgaard JP (2011) Gender difference in antidiuretic response to desmopressin. American Journal of Physiology-Renal Physiology 300(5):F1116–F1122

    Article  CAS  Google Scholar 

  41. Yamaguchi O, Nishizawa O, Juul KV, Nørgaard JP (2013) Gender difference in efficacy and dose response in Japanese patients with nocturia treated with four different doses of desmopressin orally disintegrating tablet in a randomized, placebo-controlled trial. BJU Int 111(3):474–484. https://doi.org/10.1111/j.1464-410X.2012.11547.x

    Article  CAS  PubMed  Google Scholar 

  42. Liu J, Sharma N, Zheng W, Ji H, Tam H, Wu X et al (2010) Sex differences in vasopressin V2 receptor expression and vasopressin-induced antidiuresis. Am J Physiol Ren Physiol 300(2):F433–F440. https://doi.org/10.1152/ajprenal.00199.2010

    Article  CAS  Google Scholar 

  43. Carrel L, Willard HF (2005) X-inactivation profile reveals extensive variability in X-linked gene expression in females. Nature 434(7031):400–404. https://doi.org/10.1038/nature03479

    Article  CAS  PubMed  Google Scholar 

  44. Vinter KJ, Goble S, De Bruyne P, Vande Walle J, Nørgaard JP (2013) Is there a gender difference in antidiuretic response to desmopressin in children? Open Journal of Pediatrics 3(3):224–230. https://doi.org/10.4236/ojped.2013.33039

    Article  CAS  Google Scholar 

  45. Kataoka Y, Nishida S, Hirakawa A, Oiso Y, Arima H (2015) Comparison of incidence of hyponatremia between intranasal and oral desmopressin in patients with central diabetes insipidus. Endocr J 62(2):195–200. https://doi.org/10.1507/endocrj.EJ14-0368

    Article  CAS  PubMed  Google Scholar 

  46. De Waele K, Cools M, De Guchtenaere A, Van de Walle J, Raes A, Van Aken S et al (2014) Desmopressin lyophilisate for the treatment of central diabetes insipidus: first experience in very young infants. International Journal of Endocrinology and Metabolism 12(4):e16120. https://doi.org/10.5812/ijem.16120

    Article  PubMed  PubMed Central  Google Scholar 

  47. Van de Walle J, Van Herzeele C, Raes A (2010) Is there still a role for desmopressin in children with primary monosymptomatic nocturnal enuresis? Drug Saf 33(4):261–271. https://doi.org/10.2165/11319110-000000000-00000

    Article  PubMed  Google Scholar 

  48. Sterns RH, Riggs JE, Schochet SS Jr (1986) Osmotic demyelination syndrome following correction of hyponatremia. N Engl J Med 314(24):1535–1542. https://doi.org/10.1056/NEJM198606123142402

    Article  CAS  PubMed  Google Scholar 

  49. Renneboog B, Musch W, Vandemergel X, Manto MU, Decaux G (2006) Mild chronic hyponatremia is associated with falls, unsteadiness, and attention deficits. Am J Med 119(1):71.e1-71.e8. https://doi.org/10.1016/j.amjmed.2005.09.026

    Article  CAS  Google Scholar 

  50. Winberg J (1959) The 24-hour true endogenous creatinine clearance in infants and children without renal disease. Acta Paediatr 48:443

    CAS  Google Scholar 

  51. Sharma R, Stein D (2014) Hyponatremia after desmopressin (DDAVP) use in pediatric patients with bleeding disorders undergoing surgeries. J Pediatr Hematol Oncol 36(6):e371–e375. https://doi.org/10.1097/MPH.0000000000000185

    Article  PubMed  Google Scholar 

  52. Michelet R, Dossche L, Van Herzeele C, Van Bocxlaer J, Vermeulen A, Walle JV (2018) Claiming desmopressin therapeutic equivalence in children requires pediatric data: a population PKPD analysis. Eur J Clin Pharmacol 74(3):297–305. https://doi.org/10.1007/s00228-017-2386-0

    Article  CAS  PubMed  Google Scholar 

  53. Vande Walle JG, Bogaert GA, Mattsson S, Schurmans T, Hoebeke P, Deboe V et al (2006) A new fast-melting oral formulation of desmopressin: a pharmacodynamic study in children with primary nocturnal enuresis. BJU Int 97(3):603–609. https://doi.org/10.1111/j.1464-410X.2006.05999.x

    Article  CAS  PubMed  Google Scholar 

  54. Fjellestad-Paulsen A, Höglund P, Lundin S, Paulsen O (1993) Pharmacokinetics of 1-deamino-8-d-arginine vasopressin after various routes of administration in healthy volunteers. Clin Endocrinol 38(2):177–182. https://doi.org/10.1111/j.1365-2265.1993.tb00990.x

    Article  CAS  Google Scholar 

  55. Williams T, Dunger D, Lyon C, Lewis R, Taylor F, Lightman S (1986) Antidiuretic effect and pharmacokinetics of oral 1-desamino-8-d-arginine vasopressin. 1. Studies in adults and children. J Clin Endocrinol Metab 63(1):129–32. https://doi.org/10.1210/jcem-63-1-129

  56. De Bruyne P, De Guchtenaere A, Van Herzeele C, Raes A, Dehoorne J, Hoebeke P et al (2014) Pharmacokinetics of desmopressin administered as tablet and oral lyophilisate formulation in children with monosymptomatic nocturnal enuresis. Eur J Pediatr 173(2):223–228. https://doi.org/10.1007/s00431-013-2108-2

    Article  CAS  PubMed  Google Scholar 

  57. Lam K, Wat M, Choi K, Ip T, Pang R, Kumana C (1996) Pharmacokinetics, pharmacodynamics, long-term efficacy and safety of oral 1-deamino-8-d-arginine vasopressin in adult patients with central diabetes insipidus. Br J Clin Pharmacol 42(3):379–385. https://doi.org/10.1046/j.1365-2125.1996.39914.x

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Michelet R, Dossche L, Van Herzeele C, De Bruyne P, Gasthuys E, Van Bocxlaer J et al (2020) An integrated paediatric population PK/PD analysis of dDAVP: how do pK differences translate to clinical outcomes? Clin Pharmacokinet 59(1):81–96. https://doi.org/10.1007/s40262-019-00798-6

    Article  CAS  PubMed  Google Scholar 

  59. Thumfart J, Roehr CC, Kapelari K, Querfeld U, Eggert P, Müller D (2005) Desmopressin associated symptomatic hyponatremic hypervolemia in children. Are there predictive factors? J Urol 174(1):294–8. https://doi.org/10.1097/01.ju.0000161213.54024.7f

  60. Giuliani C, Peri A (2014) Effects of hyponatremia on the brain. J Clin Med 3(4):1163–1177. https://doi.org/10.3390/jcm3041163

    Article  PubMed  PubMed Central  Google Scholar 

  61. Rembratt A, Riis A, Norgaard J (2006) Desmopressin treatment in nocturia; an analysis of risk factors for hyponatremia. Neurourology and Urodynamics: Official Journal of the International Continence Society 25(2):105–109. https://doi.org/10.1002/nau.20168

    Article  CAS  Google Scholar 

  62. Suchowersky O, Furtado S, Rohs G (1995) Beneficial effect of intranasal desmopressin for nocturnal polyuria in Parkinson’s disease. Movement disorders: Official journal of the Movement Disorder Society 10(3):337–340. https://doi.org/10.1002/mds.870100318

    Article  CAS  Google Scholar 

  63. Singer I, Oster JR, Fishman LM (1997) The management of diabetes insipidus in adults. Arch Intern Med 157(12):1293–1301. https://doi.org/10.1001/archinte.1997.00440330027003

    Article  CAS  PubMed  Google Scholar 

  64. Arima H, Wakabayashi T, Nagatani T, Fujii M, Hirakawa A, Murase T et al (2014) Adipsia increases risk of death in patients with central diabetes insipidus. Endocr J 61(2):143–148. https://doi.org/10.1507/endocrj.EJ13-0368

    Article  PubMed  Google Scholar 

  65. Dossche L, Michelet R, De Bruyne P, Van Herzeele C, Gasthuys E, Rittig S et al (2021) Desmopressin oral lyophilisate in young children: new insights in pharmacokinetics and pharmacodynamics. Arch Dis Child 106(6):597–602. https://doi.org/10.1136/archdischild-2019-318225

    Article  PubMed  Google Scholar 

  66. De Guchtenaere A, Van Herzeele C, Raes A, Dehoorne J, Hoebeke P, Van Laecke E et al (2011) Oral lyophylizate formulation of desmopressin: superior pharmacodynamics compared to tablet due to low food interaction. J Urol 185(6):2308–2313. https://doi.org/10.1016/j.juro.2011.02.039

    Article  CAS  PubMed  Google Scholar 

  67. Juul K, Schroeder M, Rittig S, Nørgaard J (2014) National Surveillance of Central Diabetes Insipidus (CDI) in Denmark: results from 5 years registration of 9309 prescriptions of desmopressin to 1285 CDI patients. J Clin Endocrinol Metab 99(6):2181–2187. https://doi.org/10.1210/jc.2013-4411

    Article  CAS  PubMed  Google Scholar 

  68. Lottmann H, Froeling F, Alloussi S, El-Radhi A, Rittig S, Riis A et al (2007) A randomised comparison of oral desmopressin lyophilisate (MELT) and tablet formulations in children and adolescents with primary nocturnal enuresis. Int J Clin Pract 61(9):1454–1460. https://doi.org/10.1111/j.1742-1241.2007.01493.x

    Article  CAS  PubMed  Google Scholar 

  69. Juul KV, Van Herzeele C, De Bruyne P, Goble S, Walle JV, Nørgaard JP (2013) Desmopressin melt improves response and compliance compared with tablet in treatment of primary monosymptomatic nocturnal enuresis. Eur J Pediatr 172(9):1235–1242. https://doi.org/10.1007/s00431-013-1992-9

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  70. Arima H, Oiso Y, Juul KV, Nørgaard JP (2013) Efficacy and safety of desmopressin orally disintegrating tablet in patients with central diabetes insipidus: results of a multicenter open-label dose-titration study. Endocr J EJ13–0165. https://doi.org/10.1507/endocrj.EJ13-0165

  71. Murakami T, Hatoko T, Nambu T, Matsuda Y, Matsuo K, Yonemitsu S et al (2014) Desmopressin orally disintegrating tablet in Japanese patients with central diabetes insipidus: A retrospective study of switching from intranasal desmopressin. Endocr J EJ14–0097. https://doi.org/10.1507/endocrj.EJ14-0097

  72. Oiso Y, Robertson GL, Nørgaard JP, Juul KV (2013) Treatment of neurohypophyseal diabetes insipidus. J Clin Endocrinol Metab 98(10):3958–3967. https://doi.org/10.1210/jc.2013-2326

    Article  CAS  PubMed  Google Scholar 

  73. Juul KV, Bichet DG, Nørgaard JP (2011) Desmopressin duration of antidiuretic action in patients with central diabetes insipidus. Endocrine 40(1):67–74. https://doi.org/10.1007/s12020-011-9492-z

    Article  CAS  PubMed  Google Scholar 

  74. Larijani B, Tabatabaei O, Soltani A, Taheri E, Pajouhi M, Bastanhagh M-H et al (2005) Comparison of desmopressin (DDAVP) tablet and intranasal spray in the treatment of central diabetes insipidus. DARU J Pharm Sci 13(4):155–159

    CAS  Google Scholar 

  75. Nilsson A, Lindner H, Wittendorff J (2019) inventors; Ferring B.V., assignee. Pharmaceutical formulations of desmopressin. United States patent US10307459B2

Download references

Author information

Authors and Affiliations

  1. Department of Paediatrics, Endocrinology Service, KK Women’s and Children’s Hospital, Singapore, Singapore

    Xinyi Chin & Fabian Yap

  2. Pharmacy Department, KK Women’s and Children’s Hospital, Singapore, Singapore

    Shao Wei Teo

  3. Nursing Specialist Service, KK Women’s and Children’s Hospital, Singapore, Singapore

    Soo Ting Lim

  4. Department of Paediatrics, Nephrology Service, KK Women’s and Children’s Hospital, Singapore, Singapore

    Yong Hong Ng

  5. Department of Urogynaecology, KK Women’s and Children’s Hospital, Singapore, Singapore

    How Chuan Han

Authors
  1. Xinyi Chin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shao Wei Teo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Soo Ting Lim
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yong Hong Ng
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. How Chuan Han
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Fabian Yap
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Xinyi Chin.

Ethics declarations

Conflict of interest

The authors declare no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Chin, X., Teo, S.W., Lim, S.T. et al. Desmopressin therapy in children and adults: pharmacological considerations and clinical implications. Eur J Clin Pharmacol 78, 907–917 (2022). https://doi.org/10.1007/s00228-022-03297-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-022-03297-z

Keywords

Search

Navigation